Skip to main content

Latest stock market podcasts

From the helm: Opthea Ltd (ASX:OPT) Chief Executive Officer, Fred Guerard

Bell Direct
February 7, 2025

In this latest instalment of Bell Direct’s From the helm series, we kick off 2025 with an exciting deep dive into the healthcare sector. Host Bell Direct’s Market Analyst, Grady Wulff sits down with Opthea (ASX:OPT) CEO, Fred Guerard to discuss the company’s remarkable 168% share price surge over the past six months as it advances toward commercialising its novel retinal disease treatment, Sozinibercept. With an initial focus on wet age-related macular degeneration, Opthea is poised to disrupt the market with its innovative approach to vision care.

In this video, Fred discusses:

  • (0:43): Opthea’s history and its mission in the healthcare space
  • (1:40): how Sozinibercept compares to existing therapies
  • (3:22): recent Phase 3 data and confidence in trial success
  • (6:22): commercialisation strategy and financial runway
  • (8:15): key milestones and future pipeline treatments.

Note: This interview was filmed on 5 February 2025.

Morning Bell 9 April

Bell Direct
April 9, 2025

Morning Bell 8 April

Bell Direct
April 8, 2025

Morning Bell 7 April

Bell Direct
April 7, 2025

Weekly Wrap 4 April

Bell Direct
April 4, 2025

Morning Bell 3 April

Bell Direct
April 3, 2025

Morning Bell 2 April

Bell Direct
April 2, 2025

Morning Bell 1 April

Bell Direct
April 1, 2025

Morning Bell 31 March

Bell Direct
March 31, 2025

Weekly Wrap 28 March

Bell Direct
March 28, 2025

Morning Bell 27 March

Bell Direct
March 27, 2025

Morning Bell 26 March

Bell Direct
March 26, 2025

Morning Bell 25 March

Bell Direct
March 25, 2025